The purpose of this study is to determine whether hypofractionated concurrent chemo-radiotherapy has the same efficiency as conventionally fractionated concurrent chemo-radiotherapy in Limited Disease Small Cell Lung Cancer.
For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm. While 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm. Both survival and toxicity of the two arms will be observed and compared.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
860
For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm.
For patients with Limited Disease Small Cell Lung Cancer, 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm.
Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences
Beijing, China
overall survival
Time frame: 2 years
disease free survival
Time frame: 2 years
local-regional failure (Incidence of tumor recurrence in local or regional area)
Incidence of tumor recurrence in local or regional area
Time frame: 2 years
toxicity (Incidence of radiotherapy and chemotherapy induced toxicities assessed by CTCAE v 4.0)
Incidence of radiotherapy and chemotherapy induced toxicities assessed by CTCAE v 4.0
Time frame: 2 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.